TABLE 1.
Key baseline demographic and clinical characteristics of the study participants
| Parameter | All participants (N = 37) | Placebo (N = 9) | Danuglipron dose | ||
|---|---|---|---|---|---|
| 40 mg BID (N = 10) | 80 mg BID (N = 9) | 120 mg BID (N = 9) | |||
| Age (years) | 55.8 (8.6) | 58.6 (8.8) | 55.9 (10.0) | 58.0 (6.7) | 50.7 (7.5) |
| Sex | |||||
| Male | 32 (86.5) | 8 (88.9) | 8 (80.0) | 8 (88.9) | 8 (88.9) |
| Female | 5 (13.5) | 1 (11.1) | 2 (20.0) | 1 (11.1) | 1 (11.1) |
| Asian race | 37 (100.0) | 9 (100.0) | 10 (100.0) | 9 (100.0) | 9 (100.0) |
| T2DM duration (years) | 5.7 (5.5) | 5.5 (4.1) | 2.9 (2.2) | 9.1 (5.8) | 5.7 (7.7) |
| MDG (mg/dl) | 220.8 (54.3) | 218.8 (59.8) | 223.4 (50.5) | 240.6 (52.3) | 200.0 (56.3) |
| FPG (mg/dl) | 173.9 (36.1) | 182.9 (36.3) | 173.3 (29.7) | 175.7 (32.7) | 163.7 (47.5) |
| HbA1c (%) | 8.3 (1.1) | 8.3 (1.2) | 8.2 (1.1) | 8.6 (1.0) | 8.4 (1.2) |
| Body weight (kg) | 78.6 (11.1) | 73.3 (9.9) | 79.7 (13.6) | 79.6 (10.0) | 81.5 (10.4) |
| BMI (kg/m2) | 27.8 (3.6) | 25.9 (2.7) | 28.6 (4.1) | 28.2 (3.6) | 28.6 (3.4) |
Note: data are n (%) or mean (SD). Baselines for body weight, FPG and HbA1c were defined as the measurement at Day −1, 0 h. Baseline for MDG was defined as glucose AUC24/24 h on Day −1.
Abbreviations: BID, twice daily; BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; MDG, mean daily glucose; SD, standard deviation; T2DM, type 2 diabetes mellitus.